{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T07:23:27Z","timestamp":1787556207177,"version":"build-2736575974"},"reference-count":5,"publisher":"PAGEPress Publications","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatol Reports"],"abstract":"<jats:p>Dear Editor,\nCalcitonin gene-related peptide (CGRP) is a neuropeptide with potent vasodilatory effects and a key role in trigeminovascular signaling, underlying the pathogenesis of migraine. Consequently, the inhibition of CGRP activity has been demonstrated to reduce the incidence of acute migraine attacks. Based on this evidence, monoclonal antibodies against CGRP or its receptor have been approved by the European Medicines Agency for prevention of both episodic and chronic migraine. Among CGRP inhibitors, galcanezumab has also been authorized for the treatment of episodic cluster headache. Since the advent of CGRP inhibitors, several cases of drug-induced telogen effluvium have been reported, with incidence rates ranging from 1.10% to 7.23%. However, to the best of our knowledge, alopecia areata (AA) associated with CGRP inhibition remains undescribed in the literature. [...]<\/jats:p>","DOI":"10.4081\/dr.2026.10802","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T07:15:48Z","timestamp":1787555748000},"source":"Crossref","is-referenced-by-count":0,"title":["New-onset alopecia areata during calcitonin gene-related peptide inhibitor therapy: first reported case"],"prefix":"10.4081","author":[{"given":"Luca","family":"Valtellini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Barbareschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Mariel","family":"Ferrucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo Valerio","family":"Marzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Sechi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2549","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"42792","doi-asserted-by":"crossref","unstructured":"1. Sun W, Li Y, Xia B, et al. Adverse event reporting of four anti-calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system. Front Pharmacol 2023;14:1257282.","DOI":"10.3389\/fphar.2023.1257282"},{"key":"42793","doi-asserted-by":"crossref","unstructured":"2. Woods RH. Alopecia signals associated with calcitonin gene-related peptide inhibitors in the treatment or prophylaxis of migraine: A pharmacovigilance study. Pharmacotherapy 2022;42:758-67.","DOI":"10.1002\/phar.2725"},{"key":"42794","doi-asserted-by":"crossref","unstructured":"3. Harada N, Okajima K, Arai M, et al. Administration of capsaicin and isoflavone promotes hair growth by increasing insulin-like growth factor-I production in mice and in humans with alopecia. Growth Horm IGF Res 2007;17:408-15.","DOI":"10.1016\/j.ghir.2007.04.009"},{"key":"42795","doi-asserted-by":"crossref","unstructured":"4. Kinori M, Bertolini M, Funk W, et al. Calcitonin gene-related peptide (CGRP) may award relative protection from interferon-\u03b3-induced collapse of human hair follicle immune privilege. Exp Dermatol 2012;21:223-6.","DOI":"10.1111\/j.1600-0625.2011.01432.x"},{"key":"42796","doi-asserted-by":"crossref","unstructured":"5. Meyronet D, Jaber K, Gentil-Perret A, et al. Decreased CGRP staining in alopecia areata. Br J Dermatol 2003;149:422-4.","DOI":"10.1046\/j.1365-2133.2003.05425.x"}],"container-title":["Dermatology Reports"],"original-title":[],"link":[{"URL":"https:\/\/journals.pagepress.net\/dr\/article\/download\/10802\/9996","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.pagepress.net\/dr\/article\/download\/10802\/9996","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T07:15:49Z","timestamp":1787555749000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.pagepress.net\/dr\/article\/view\/10802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":5,"URL":"https:\/\/doi.org\/10.4081\/dr.2026.10802","relation":{},"ISSN":["2036-7406","2036-7392"],"issn-type":[{"value":"2036-7406","type":"electronic"},{"value":"2036-7392","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,24]]}}}